Sample size was calculated based on the provided parameter: significance level (adjusted for sidedness) = 0.025, standard deviation for MAGE = 24mg/dL, power = 0.8, and a between-group difference in mean MAGE equal to 14.5 mg/dL. The variable calculated was the total number of patients. A total of 44 patients in each group (dapagliflozin 10 mg or gliclazide MR 120 mg) must complete this two-treatment parallel-design study. Considering an expected screening failure rate of 30% (n=11 per group) and an expected dropout rate of 8% (n=5 per group), based in previous studies in our center using similar populations and period, a total of 60 patients per group (120 total) will be enrolled.